This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Bookman MA , McGuire WP , Kilpatrick D , Keenan E , Hogan WM , Johnson SW , Odwyer P , Rowinsky E , Gallion HH , Ozols RF
Carboplatin and paclitaxel in ovarian carcinoma: A phase I study of the Gynecologic Oncology Group
Journal of Clinical Oncology. 1996 Jun;14(6) :1895-1902
AbstractPurpose: To develop a tolerable, dose-intense regimen of carboplatin and paclitaxel for the treatment of primary epithelial ovarian carcinoma. Patients and Methods: Patients underwent initial surgical assessment and tumor debulking. patients with stage III/IV disease received six cycles of chemotherapy on a planned 21-day cycle. Carboplatin dose was calculated based on projected area under the curve (AUG) for concentration over time (mg . mL(-1). min) and escalated to determine the maximum-tolerated dose (MTD). Paclitaxel dose was also escalated as a 3-, 24-, or 96-hour infusion, Granulocyte colony-stimulating factors (G-CSFs) were required at selected dose levels or could be added based on hematologic toxicity. Results: Thirty-nine patients were enrolled and assessable for toxicity and response. Dose-limiting toxicity (DLT) was hematologic, primarily neutropenia. Less than 2% of all cycles with paclitaxel as a 3- or 24-hour infusion were associated with either grade 4 thrombocytopenia or febrile neutropenia. The carboplatin MTD was AUC 7.5 (equivalent to a median dose of 471 mg/m(2)). The MTD for paclitaxel was 135 mg/m(2) over 24 hours and 175 mg/m(2) over 3 hours without initial G-CSF. A 96- hour infusion of paclitaxel at a dose of 120 mg/m(2) was associated with excessive single-cycle and cumulative myelosuppression, and was not further evaluated, Measured carboplatin AUC agreed well with the calculated AUC. The overall complete (n = 16) and partial (n = 2) response rate among 24 patients with measurable disease was 75%, with a median progression-free survival time of 15 months. Conclusion: Carboplatin could be safely combined with paclitaxel using a dose formula based on projected renal clearance, The recommended outpatient regimen is carboplatin AUC 7.5 and paclitaxel 175 mg/m(2) over 3 hours without initial G-CSF. This treatment safely achieved a greater dose-intensity of carboplatin than would have been achieved with conventional dosing based on body-surface area. (C) 1996 by American Society of Clinical Oncology.
NotesTimes Cited: 104 English Article UP725 J CLIN ONCOL